MU
42
14
CRM
65
6
GOOGL
62
6
CINF
24
-8
AIV
39
6
MCD
52
3
LMT
29
-5
HUM
25
4
PNC
48
6
BXP
39
5
NEE
39
9
AMGN
42
14
MAT
41
2
FCX
44
4
CCI
30
2
GS
65
16
CCL
68
6
CAG
34
3
CME
59
3
L
54
5
MU
42
14
CRM
65
6
GOOGL
62
6
CINF
24
-8
AIV
39
6
MCD
52
3
LMT
29
-5
HUM
25
4
PNC
48
6
BXP
39
5
NEE
39
9
AMGN
42
14
MAT
41
2
FCX
44
4
CCI
30
2
GS
65
16
CCL
68
6
CAG
34
3
CME
59
3
L
54
5
Financhill
Back

MediPharm Labs 10K Form

Sell
16

MEDIF
MediPharm Labs

Last Price:
$0.04
Seasonality Move:
14.13%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MEDIF News And Ratings

See the #1 stock for the next 7 days that we like better than MEDIF

MEDIF Financial Statistics

Sales & Book Value

Annual Sales: $24.5M
Cash Flow: $-516.2K
Price / Cash Flow: 0
Annual Sales: $0.08
Price / Book: 0.53

Profitability

EPS (TTM): -0.02940
Net Income (TTM): $-8.6M
Gross Margin: $4.3M
Return on Equity: -23.29%
Return on Assets: -18.91%

MediPharm Labs Earnings Forecast

Key MediPharm Labs Financial Ratios

  • The Gross Profit Margin over the past 6 years for MEDIF is 17.71%.
  • The Selling, General & Administrative Expenses for MEDIF have been equal to 75.00% of Gross Profit Margin.
  • The Research & Development expenses have been 0.63% of Revenue.
  • The Interest Expense is -2.79% of Operating Income.
  • The Net Earning history of MEDIF is -39.57% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 4 years.

MediPharm Labs Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: MEDIF
Website: medipharmlabs.com

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 3.21
Quick Ratio: 1.84

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

MEDIF Technical Analysis vs Fundamental Analysis

Sell
16
MediPharm Labs (MEDIF) is a Sell

Is MediPharm Labs a Buy or a Sell?

  • MediPharm Labs stock is rated a Sell
    The current MediPharm Labs [MEDIF] share price is $0.04. The Score for MEDIF is 16, which is 68% below its historic median score of 50, and infers higher risk than normal.